Related Experiment Video
Updated: Aug 15, 2026

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction
Published on: May 17, 2024
Finding the Sweet Spot? Differential Diabetes Risks in Autologous Breast Reconstruction
Victoria Kong1, Jun Jiang2, Tobias Niederegger3
1Division of Plastic Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT.
Background:
Autologous breast reconstruction (ABR) offers superior quality of life compared with implant-based reconstruction or mastectomy alone but carries substantial perioperative risk. Diabetes mellitus is a known predictor of postoperative morbidity but is often treated as a binary variable, obscuring differences between patients on oral antihyperglycemic agents (diabetes managed with oral antihyperglycemic agents [DM-ORAL]) and insulin (diabetes requiring insulin therapy [DM-INS]).
Materials And Methods:
Using the National Surgical Quality Improvement Program, we identified female breast cancer patients undergoing immediate ABR (2008-2021). Diabetes status was categorized as nondiabetic, DM-ORAL, or DM-INS. Primary outcomes were 30-day adverse events, reoperation, unplanned readmission, and surgical and medical complications. Groups were compared and multivariable regression used to adjust for confounders.
Results:
Of 8121 patients, 559 (6.9%) had diabetes, including 457 (81.8%) DM-ORAL and 102 (18.2%) DM-INS. Diabetes prevalence increased over time with a 0.3 percentage-point annual rise (R2 = 0.58; P = .003), driven mainly by DM-ORAL (R2 = 0.52; P = .005), while DM-INS showed a nonsignificant trend (R2 = 0.28; P = .07). Compared with nondiabetic patients, diabetics had higher overall complication rates (34.7% vs. 24.1%), including medical (6.4% vs. 2.8%) and surgical complications (23.6% vs. 15.2%) (all P < .0001). Within diabetics, DM-INS demonstrated higher morbidity, including unplanned readmission (14.7% vs. 6.3%, P = .008) and superficial infection (10.8% vs. 5.3%, P = .04) compared to DM-ORAL. On multivariable analysis, diabetes independently predicted complications (OR 1.4), with higher risk in DM-INS (OR 1.9) than DM-ORAL (OR 1.3); DM-INS more than doubled surgical complication risk (OR 2.5).
Conclusion:
Diabetes is a significant but heterogeneous risk factor in ABR, with insulin-treated patients at particularly elevated perioperative risk, supporting treatment-specific risk stratification.
More Related Videos
06:03Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
Published on: February 6, 2020
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025